Ocular manifestations of Parkinson disease by Al-Namaeh , Mashael
 
 
Med Hypothesis Discov Innov Optom. 2020; 1(1)  
 





Ocular manifestations of Parkinson disease 
Mashael Al-Namaeh 1  
 
1  Oulu University of Applied Sciences, Oulu, Finland 
ABSTRACT 
Background: Parkinson's disease (PD) is the second most common neurodegenerative disorder. We aimed to review both the 
disease and the drug-related ocular manifestations of PD. 
Methods: In this manuscript, we have reviewed and summarized existing literature on the ocular manifestations and drug-
related complications of PD. We have also discussed the use of current noninvasive imaging techniques, such as optical 
coherence tomography (OCT), for the early diagnosis and monitoring of PD. 
Results: Impaired color vision, reduced stereopsis, reduced contrast sensitivity, pupillary abnormalities, eye movement 
disorders, convergence insufficiency, dry eye syndrome, glaucoma, visual dysfunctions, retinal abnormalities, and drug-
related side effects were among the listed ocular manifestations of PD. There is a large knowledge gap regarding the type of 
glaucoma affecting PD patients—whether it is open-angle or other types. Further case studies and long-term follow-ups 
during PD progression are necessary to fill this gap. Patient compliance with follow-up visits for more visual field tests and 
OCT during PD progression may become problematic when dementia and cognitive impairment occur. 
Conclusions: There is a general need for clinicians to perform further tests and more visual examinations to rule out ocular 
manifestations. Furthermore, additional clinical trials are needed to further evaluate the use of different types of OCT findings 
as biomarkers of PD progression. This would aid in early diagnosis and in delaying disease progression, if treated promptly. 
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INTRODUCTION 
Parkinson's disease (PD) is the second most common 
neurodegenerative disorder. PD is thought to be one of the 
40 conformational diseases induced by the accumulation of 
unfolded or misfolded proteins. Improper misfolding and 
accumulation of unfolded proteins may result in the 
formation of disordered (amorphous) or ordered (amyloid 
fibril) aggregates. In PD, amyloidogenic protein accumulation 
often occurs in the brain tissues with the deposition of alpha-
synuclein. Unfolded or misfolded protein aggregation also 
occurs in different parts of the eye, such as the lens, in case 
of cataracts [1, 2]. PD is characterized by depletion of 
dopaminergic neurons in the mid-brain basal ganglia—
substantia nigra pars compacta. In addition, owing to the 
decreased levels of dopamine, motor symptoms also 
developed, such as resting tremor, bradykinesia, and 
rigidity. Deposition of α-synuclein and dopamine deficiency 
in the retina reflects the pathological characteristics of PD in 
the brain. These findings together support the idea that the 
eye can act as a gateway to the brain, providing physicians 
with noninvasive methods for further assessment. Vision is 
one of the nonmotor systems altered in PD patients. Vision is 
affected due to decreased dopamine levels, which results in 
decreased visual acuity, impaired contrast and color vision, 




Med Hypothesis Discov Innov Optom. 2020; 1(1)  
2 OCULAR MANIFESTATIONS OF PARKINSON’S DISEASE  
Color vision and contrast sensitivity are modulated by the 
dopaminergic receptors (D1 and D2), which are differentially 
located in the retinal layers. The absence of dopaminergic 
receptor activation by dopamine results in signal dispersion 
and alterations in color vision and contrast sensitivity [4]. 
Dry eyes, blepharospasm, cataract, diplopia, glaucoma, 
glaucoma-like visual problems, visuospatial and 
visuoperceptual impairments, and visual hallucinations are 
other ocular manifestations of PD [5-8]. Ocular changes, 
including visual dysfunction, pupil abnormality, lens opacity, 
and retinal neuronal loss and dysfunction, have been 
reported in patients with PD. Other manifestations include 
seborrheic dermatitis and blepharitis [6], lid retraction [9], 
decreased blinking rate [10], limited upgaze [11], and drug-
related adverse effects caused by cholinergic drugs, 
levodopa, amantadine, and others used in the management 
of PD. The risk of PD dementia can be evaluated using visual 
measures and assessment of the retinal structures of the 
ganglion cell layer and inner plexiform layer in the 
dopaminergic layers [12]. The study of ocular motor 
manifestations, particularly eye movements, can help to 
clarify the evolving clinicopathologic spectrum of disorders of 
atypical Parkinsonian and can serve as a tool for early 
detection of PD. The most common oculo-visual problems 
associated with PD dementia are eye movements, visual 
hallucinations, visuospatial function, and variations in 
saccadic eye movement dysfunction, which are valuable 
diagnostic characteristics for identifying Parkinsonian 
symptoms [13]. In addition, clinicians should pay special 
attention to the diagnosis and treatment of glaucoma and 
dry eye syndrome in patients with PD [14]. Recent research 
has focused on high-resolution imaging and other 
technological advancements to increase the sensitivity of 
ocular motility tests. Eye movements have been studied in 
clinical care and clinical trials as biomarkers for the diagnosis 
and progression of PD [15].  
The main types of drugs used to treat PD are levodopa (L-
DOPA), dopamine agonists, anticholinergics, monoamine 
oxidase type B (MAO-B) inhibitors, and catechol-O-
methyltransferase (COMT) inhibitors. Drug-related 
complications, such as hallucinations and psychosis, have 
been reported [16]. Moreover, drug-related ocular 
manifestations, such as blurred vision, closed-angle 
glaucoma, and visual hallucinations, have been detected in 
patients [16]. Finally, convergence insufficiency (CI) has also 
been reported in cases of idiopathic PD responsive to 
levodopa [17]. 
The primary objective of this manuscript was to review the 
ocular manifestations of PD and the drugs-related ocular 
complications, as well as to explore the modalities that are 
suitable for identifying PD progression. 
METHODS 
We conducted an electronic search using PubMed and 
Google Scholar and limited the search to papers in English, 
with no specific period. We used the following keywords: 
“Parkinson's Disease”, AND “ocular manifestations” of PD 
including glaucoma, hallucinations, decreased visual acuity, 
color vision sensitivity, contrast sensitivity, stereopsis 
impairment, dry eye Syndrome, blepharitis, cataract, 
diplopia, and pupil abnormalities;  “Parkinson's Disease”, 
AND  “Eye movement abnormalities” including double vision, 
color sensitivity, CI, saccade, smooth pursuit eye movement 
vergence abnormalities, strabismus, reading time 
(decreased), vertical gaze abnormalities , and rapid eye 
movement; “Parkinson’s Disease” AND “Ocular biomarkers”; 
as well as, “Parkinson’s Disease” AND “drug-related ocular 
complications”, including; hallucinations, psychosis, 
dopamine-dysregulation syndrome, blurred vision, close-
angled glaucoma, and visual hallucinations.  
 
RESULTS 
We included original papers that met the following criteria: 
studies on human subjects, studies that clearly addressed PD 
(ocular manifestations), and studies that included anti-
Parkinsonian agents (drug-related complications). We 
excluded 2411 articles that were not original research 
papers, did not have human subjects, evaluated more than 
one drug treatment (for drug-related complications), or had 
a trial dose of any anti-parkinsonian agent (for ocular 
manifestations of PD). Our search retrieved 2509 articles, of 
which, after considering the stated inclusion criteria and 
removal of duplicates, 98 articles were finally included in the 
review. Table 1 summarizes the ocular manifestations of PD.  
The drug-related complications are summarized in Table 
2. The suggestive visual screening tests for each ocular 
manifestation are summarized in Table 3. 
DISCUSSION 
PARKINSON’S DISEASE AND OCULAR MANIFESTATIONS  
Impaired Color Vision, Low contrast, and Stereopsis    
Stereopsis impairment was reported in patients with PD [18] 
and was closely linked to color perception and motor 
dysfunction [19]. Impaired color vision and contrast 
sensitivity was also reported [3, 5, 20, 21]. In addition, the 
low-contrast charts detected a visual loss in patients with PD, 
including those with normal visual acuity [22]. In addition, 
contrast sensitivity is diminished in PD, most at intermediate 
spatial frequencies [23]. Table 1 summarizes the ocular 
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Pupil reactivity 
PD patients show normal sympathetic arousal to affective 
stimuli, which are documented by pupil diameter, but with 
variations in eye movements [24, 25]. In patients with PD, 
several signs of abnormal pupil reactivity have been 
identified. Following light adaptation, the pupil diameters 
were found to be either larger or unequal in size, and a 
significant increase in light reflex latency, whereas decreased 
amplitude, maximum constriction velocity, and maximum 
acceleration were also observed [25-28].  
Moreover, pupillary abnormalities can precede motor 
symptoms and may occur early in the disease [29]. Pupillary 
abnormalities are useful as they are potential nonmotor 
biomarkers for prompt identification and disease progression 
monitoring in patients with PD due to their modern, quick, 
non-invasive, and low-cost techniques used for detection 
[25, 29, 30]. 
Eye movements  
In PD patients, abnormalities are more noticeable in the 
initial stages of voluntary saccades than reflexive saccades. In 
advanced stages, the involvement of visually guided saccades 
is seen. Saccadic hypometria, reduced accuracy, and 
increased latency are among the most common deficits in PD 
patients. PD patients often have atypically frequent and large 
square-wave jerks and impaired reflexive saccade inhibition 
when voluntary mirror saccades are required. Poor 
convergence and pursuit are common [31]. Impairment of 
saccadic and smooth pursuit eye movements has been 
evident [32], in addition to square-wave jerks and ocular 
oscillations [33, 34]. Saccadic reading in PD is slower. The 
reading time was slower in PD with CI by 8 s [35]. In a study, 
PD patients developed vertical gaze abnormalities, while the 
diagnosis was changed from PD to progressive supranuclear 
palsy-Parkinsonism during a 4-year follow-up [36]. In PD 
patients, vergence abnormalities and strabismus are related 
to CI, and diplopia has also been reported [37]. 
Patients with PD and without dementia had prolonged visual 
fixation duration, which correlated with visual recognition 
memory tasks. The clinical use of eye movement parameters 
as an early marker of cognitive decline in PD requires further 
exploration [38]. The oculomotor cogwheel phenomenon 
and ocular bradykinesia have been reported as 
manifestations of extrapyramidal disease [39]. In addition, 
difficulty in the initiation and execution of movements in PD 
patients is also mentioned in the literature [40]. 
Convergence Insufficiency (CI) 
Cognitive impairment has been shown to commonly co-
occur with CI in Parkinsonian disorders and is associated with 
significantly greater near point of convergence (NPC) 
distances [41]. Clinicians should take serious note of cognitive 
impairment in patients with CI objective findings, whether 
symptomatic or not. Diplopia has been reported in patients 
with PD [20, 42]. It is associated primarily with CI [10, 20]. PD 
patients are reported to have a reduction in vision-related 
quality of life, which is not associated with visual acuity [43], 
most likely due to convergence debility.  
Dry Eye Syndrome  
Signs of dry eyes, abnormal ocular surface staining, and 
meibomian disease are commonly seen in patients with PD. 
Patients with PD had lower blink rates and decreased corneal 
sensitivity. Blink rate correlated with the sensitivity of the 
corneas, which could be associated with asymptomatic 
ocular surface disease due to diminished corneal sensitivity. 
The loss of corneal nerves was not attributed to a lack of 
corneal sensitivity but was correlated with a diminished blink 
rate [27, 44]. Blepharitis has also been reported in patients 
with PD [10]. Blepharospasms has also been reported in 
patients with PD, which might lead to excessive blinking due 
to ocular irritation in dry eyes [45, 46].  
Glaucoma 
Open-angle glaucoma is not a predictor of PD [47-49]. Other 
studies have found that the occurrence of PD is correlated 
with a small but statistically significant increase in elderly 
people with glaucoma [50]. PD patients can show 
glaucomatous-like perimetric defects, often in the absence of 
reduced RNFL thickness [51]. In addition, Beyer et al., 2002 
concluded that Alzheimer's disease and PD patients may 
have an increased risk of glaucoma occurrence [52]. Yenice 
et al. concluded that patients with PD had worse visual field 
indices indicating a common insult to the nerve fiber, which 
is the same etiopathogenesis observed in glaucoma and PD 
[53]. The proposed mechanism underlying this presentation 
was linked to microorganisms that cause glaucoma via the 
gut-retina axis, leading to the generation of autoantibodies 
and autoreactive T cells, which consequently result in 
autoimmune destruction [54, 55].  
Visual Perception, Visual Hallucination, and Visual Fatigue  
Several visual dysfunctions in PD are of clinical relevance, 
such as vague visual complaints, blurred vision, impaired 
contour perception, distress in a striped surrounding, and 
visual hallucinations [8, 56]. Errors in visual input processing 
could enhance the risk of misinterpretation and even cause 
visual hallucinations because of various clinical signs, such as 
misperception of depth, repeated falls, and enhanced motor 
impairment. It is strongly recommended that all visual 
deficits be corrected as much as possible. Vision loss should 
be actively explored and fixed as fast as possible as prolonged 
visual deficits can be a probable and reversible cause of visual 
hallucinations [7]. Visual fatigue has not been reported in 
patients with PD [57].  
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In addition, the directional bias of initial visual exploration 
has been reported as a symptom of neglect in PD [58] and 
visuospatial dysfunction [59].  
Retina  
In PD, microglia have been reported to play a role in retinal 
neurodegeneration as a common pathogenic mechanism in 
PD that plays an important role in neuroinflammation in the 
form of microglial activation [60].  A meta-analysis of 
spectral-domain optical coherence tomography (SD-OCT) 
studies found that PD patients had significant thinning of the 
inner retinal layers, similar to the changes found in patients 
with glaucoma and other neurodegenerative diseases [61]. 
PD can be combined with reduced thickness and volume of 
the macula [62] and reduced RNFL thickness in the inferior 
quadrant of the retina [63]. In addition, PD patients retain 
foveal symmetry between their eyes [64]. The thickness of 
the retinal layers, visual evoked potentials, and RNFL 
thickness was similar in both the PD and control groups [65]. 
There is a correlation between macular thinning, disease 
progression, and severity in patients with PD [62]. In addition, 
there is also a link between PD severity and changes in foveal 
thickness [66]. Few studies using SD-OCT have reported a 
significant reduction in the inferior peripapillary RNFL 
thickness, including mean and temporal reduction [67]. 
There is a major decrease in retinal thickness in the macular 
area and total macular volume in PD [67-70]. The macular 
thinning in PD did not show similar differences in the 
peripapillary RNFL measurements in all studies [71-73].
                     Table 1. Ocular manifestations of Parkinson’s Disease. 
No Study and Date Ocular Manifestations 






Gobel et al., 2014 [3] 
Weil et al., 2016 [5] 
Ekker et al., 2017 [20] 
Pieri et al., 2000 [21] 
Pfeiffer et al., 2016 [74] 




Regan et al., 1984 [22] 
Bulens et al., 1988 [23] 
Pfeiffer et al., 2016 [74] 
Contrast Sensitivity 
10 Sun et al., 2014 [19] Stereopsis Impairment 






Dietz et al., 2011 [24] 
Giza et al., 2011 [25] 
Micieli et al., 1991[26] 
Biousse et al., 2004 [27] 
Fotiou et al., 2009 [28] 
Pupil Abnormalities 










Pretegiani et al., 2017 [31] 
Jehangir et al., 2018 [35] 
Pretegiani et al., 2017 [31] 
Holden et al., 2019 [41] 
Urwyler et al., 2014 [75] 
Kang et al., 2018 [37] 
Kang et al., 2018 [37] 
Jehangir et al., 2018 [35] 
Quattrone et al., 2019 [36] 
Saccade  
Saccade  
Smooth Pursuit Eye Movement   
Convergence Insufficiency  
Difficulty with Reading, Diplopia, Floater 
Vergence Abnormalities   
Strabismus  
Reading Time (Decreased)  




Biousse et al., 2004 [27] 
Rana et al., 2012 [45] 





Reddy et al., 2013 [44] 
Borm et al., 2019 [10] 
Moreau et al., 2012 [2] 







Lai et al., 2017 [50] 
Tsironi et al., 2012 [51] 
Bayer et al., 2002 [52] 
Yenice et al., 2008 [53] 
Glaucoma 
35 Crevits et al., 2003 [7] Visual Dysfunction: Visual Hallucination 
36 Ebersbach et al., 1996 [58] Visual Perception: Directional Bias 
37 Crucian et al., 2003 [59] Visuospatial Dysfunction 
38 Regan et al., 1984 [57] Visual Fatigue was not Reported 
39 Satue et al., 2016 [62] Reduced Thickness and Volume of the Macula 
40 Chrysou et al. 2019 [61] Thinning of the Inner Retinal Layers 
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DRUGS-RELATED COMPLICATIONS  
L-DOPA was found to be the most effective treatment for 
PD since 1960 [76, 77]. The chronic usage of current anti-
Parkinsonian medications, in addition to psychomotor and 
autonomic complications, causes the "wearing-off 
phenomenon" [78]. Common side effects of motor 
complications due to levodopa include motor fluctuations 
and dyskinesia, nausea, psychosis, and impulse control 
disorders, and related behaviors [79]. Although the 
therapeutic use of L-DOPA may ultimately be restricted by 
the development of numerous complications associated 
with the medication, including response fluctuations, 
dyskinesia, and psychiatric problems, it is still the drug of 
choice [80]. Psychosis is typically drug-induced and can be 
controlled by reducing anti-Parkinsonian prescription 
therapeutics [77]. Side effects of non-ergot dopamine 
agonists (Pramipexole) have been reported, including 
hallucinations, edemas, and drowsiness [81]. Benbir et al. 
(2006) reported that dopaminergic drugs and levodopa 
were not related to hallucinations in patients with PD [82].  
Anticholinergic medications have both central and 
peripheral side effects, particularly in elderly patients, 
which have restricted their significant usage. Some of the 
adverse effects of these drugs are dry mouth, decreased 
salivary secretion, blurred vision, constipation, urinary 
retention, closed-angle glaucoma, sedation, delirium, 
hallucinations, and memory loss. Finally, anti-
Parkinsonian drugs significantly contribute to the onset of 
these symptoms. This hinders the differentiation between 
PD progression and the complications associated with 
drugs [85, 87]. The drug-related complications are 
summarized in Table 2.  
Drug-Related Ocular Complications 
As shown in Table 2, ocular complications have been 
reported following the use of levodopa such as CI and visual 
hallucinations [17, 85, 86]. Visual hallucinations have been 
reported using dopamine agonists [83, 85, 86]. 
Dopaminergic medications were studied during the “ON 
and “OFF” states in PD; the results showed that during the 
ON state, mean convergence amplitude and NPC were 
better than those during the OFF state [43]. In addition, the 
convergence ability has been reported to be poor in both 
the “ON” and “OFF” states [43]. Impairment of smooth 
pursuit eye movements and difficulty in alternating 
voluntary gaze shifts have been reported in PD patients 
receiving dopaminergic medications [88]. 
Visual hallucinations have also been reported using 
monoamine oxidase inhibitors and anticholinergic agents 
[83]. Blurred vision and closed-angle glaucoma have been 
reported with the use of anticholinergics and amantadine 
(an anti-viral agent) [83].  
Levodopa has been shown to cause abnormal involuntary 
eye movements (AIEMS) in advanced PD patients during 
the ON state only, while during the OFF state the AIEMS 
disappeared completely [87]. Amantadine has been 
reported to cause corneal endothelial edema [89]. 
Table 2. Drug-related complications in Parkinson’s Disease. 










Cognitive and behavioral problems.  
Autonomic and psychomotor complications such as motor fluctuations and dyskinesia as well as nausea and psychosis. 
Impulse control disorders.  
Convergence insufficiency. 








Cognitive and behavioral problems.  
Cardiac valve fibrosis.  
Nausea, vomiting, orthostatic hypotension, confusion, and visual hallucinations. 
Hallucinations, and psychosis. 
Impairment of smooth pursuit eye movements and difficulty alternating voluntary gaze shifts. 





Hallucinations and psychosis. 
Anticholinergics [83] Mouth dryness, salivary secretion decreases, blurred vision, constipation, urinary retention, closed-angle glaucoma, sedation, 
delirium, visual hallucinations, memory loss, nightmares, and confusion. 





Ankle edema, livedo reticularis, orthostatic hypotension, congestive heart failure, mouth dryness, salivary secretion 
decreases, blurred vision, constipation, urinary retention, closed-angle glaucoma. 
Corneal endothelial edema. 
Note: The drug-related ocular complications are in colored text 
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VISUAL SCREENING TESTS AND OCULAR BIOMARKERS 
Table 3 summarizes the suggestive visual screening tests for 
each ocular manifestation. Visual acuity, cover, contrast, 
stereopsis, pupil, and color tests are required for entrance 
tests to determine visual status and pupil function. Other 
tests include 3-dimensional (3D) movies on 3D TV tests for 
stereopsis stimulation rather than the Titmus fly test [90]. 
Moreover, binocular vision tests, such as positive fusional 
vergence (PFV) and NPC, are required for CI diagnosis. It has 
been emphasized that simple reading tasks using 120 
single-digit numbers can play the role of a screening tool in 
clinical practice to assess functional ocular motor difficulties 
in PD, which can have a considerable effect on the quality 
of life [35] and electrophysiological recordings such as 
electrooculogram, flash, pattern and multifocal 
electroretinogram, or visual evoked potential. An anterior 
segment slit-lamp examination is needed for dry eyes and 
cataracts. For glaucoma and retinal evaluation, posterior 
segment examination is needed and ideally, supported by 
OCT and fundus imaging. Other tests are also used, such as 
tear film tests and perimetry [90]. Finally, the Pareidolia 
test, the Neuropsychiatric Inventory Interview, and the 
North-East Visual Hallucinations interview are needed to 
determine visual hallucinations [91-93].   
OCT is a non-invasive imaging technique that is used as a 
potential early biomarkers for the progression of PD [62, 94-
96]. The thickness of the RNFL and macular thickness 
measured by OCT may serve as biomarkers for the early 
detection and progression of a variety of neurological 
diseases [62, 94]. In PD, combining retinal structural and 
functional biomarkers can enhance the diagnostic yield. The 
tremor could prevent the acquisition of high-quality 
images. Therefore, non-imaging parameters may also 
become necessary in cases of advanced disease [95]. OCT-
angiography (OCT-A) provides depth-resolution images of 
blood flow in the optic nerve, choroid, and retina. In the PD 
cascade, retinal capillary impairment appears to occur 
early. These findings suggest that OCT-A could represent a 
new path for PD investigation and will likely be useful in the 
future as a valuable technique for early disease biomarker 
detection and for the progression of the disease [96].   
Fourier-domain OCT has been shown to be a valid and 
reproducible device for the detection of subclinical RNFL 
atrophy in PD patients [62, 65, 97], especially the Spectralis 
Nsite Axonal Analytics Module. Given the large similarity 
between the measurements of the two instruments, there 
was a significant difference between the Cirrus and 
Spectralis devices in the RNFL thickness measurements 
[97]. As a possible biomarker for PD diagnosis, RNFL 
thickness and the inner layers of the macular area have 
been used [66]. 
Without any visible changes in the routine 
ophthalmological examination, visual deficits may occur in 
PD, which can explain why electrophysiological recordings 
are needed at least partially to evaluate visual dysfunction 
during PD [14]. In addition, the development of early 
biological markers of saccadic eye movements for specific 
pathophysiological states, such as saccadic eye movement 
circuitry includes both cortical and subcortical brain 
regions, and saccadic task manipulation offers insight into 
information processing in the impaired brain. A brain 
functioning at different levels in PD can be determined by 
reflexive and voluntary saccadic tasks [98]. 
This study had some limitations. First, it was analyzed by 
one author, which may have led to bias. The strength of this 
study was that it included all the ocular manifestations and 
the required visual tests during the exam, which makes it 
easier for clinicians to use in the examination room. In 
addition, it highlighted the need for more future studies on 
PD ocular manifestations, as for certain ocular 
manifestations, there was only one reference. Further 
studies are required to determine whether accommodation 
is impaired in PD. Additional case studies are also required 
in this area.  
CONCLUSIONS 
There is a huge knowledge gap regarding the type of 
glaucoma that occurs in PD—whether it is open-angle 
glaucoma or other types. This gap needs to be filled via 
further case studies and longitudinal reports of PD 
progression. Problems with patient compliance with the 
follow-up visits to perform more visual field tests and OCT, 
as PD progresses, dementia, may arise as cognitive 
impairment develops. Finally, we concluded that there is 
a general need for clinicians to conduct further tests, and 
for the awareness of the necessity to include the listed 
visual examinations and visual tests to rule out ocular 
manifestations in PD. In addition, more clinical trials are 
needed to further evaluate the different types of OCT as 
biomarkers in PD progression, as this would aid in early 
diagnosis and delay the potential progression of the 
disease if treated early. 
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Table 3. Parkinson’s Disease ocular abnormalities and visual tests. 
Ocular manifestations in PD  References  Visual Tests 
Decreased Visual Acuity [74] Visual Acuity Test 
Color Vision Sensitivity   [3, 5, 20, 21, 74] Color Vision Test 
Contrast Sensitivity [22, 23, 74] Contrast Sensitivity Test 
Stereopsis Impairment [19] Stereopsis Test 
Diplopia [20, 75] Cover Test 
Pupil Abnormalities [24, 28] Pupil Test 
OCULOMOTOR ABNORMALITIES  
Saccade  
Smooth Pursuit Eye Movement   
Convergence Insufficiency  
Vergence Abnormalities   
Strabismus  
Reading Time (Decreased)  










Saccade Test and Reading Time Test 
Pursuit Test 
Binocular Vision Exam 
Binocular Test  
Cover Test/ Binocular Vision Exam  
Reading Time Test  
Cover Test and Binocular vision Exam 
Blepharospasm [27, 45, 46] SLE 






SLE, Tear Test, Tear Breakup Time Test (TBUT), Blink Rate Test 
SLE 
SLE 
Glaucoma [50-53] Posterior Segment Exam and OCT of the ON/Anterior Segment OCT for 
Angle/Fundus Image/IOP measure 
Visual Dysfunction: Visual Hallucination [7, 91-93] Pareidolia Test 
Neuropsychiatric Inventory Interview  
North-East Visual Hallucinations Interview  
Visual Perception: Directional Bias [58] Visual Perception Test 
Visuospatial Dysfunction [59] Visuospatial Test 
Reduced Thickness and Volume of The Macula [62] OCT of Macula 
Thinning of the Inner Retinal Layers [61] OCT of Retina 
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